Published Date: November 2024
Duchenne Muscular Dystrophy Treatment Market was valued at USD 2.1 Billion in 2024 and is projected to grow at a CAGR of 42.10% to reach USD 71.1 Billion by 2034.
The rising burden of Duchenne muscular dystrophy (DMD) disease is the major factor driving the growth of the target market. The increasing prevalence of chronic diseases, such as cardiovascular and neurovascular diseases, and arthritis are the major factors boosting the growth of the target market. However, factors such as changing government regulations and norms restrain market growth.
Key Highlights:
- In April 2019 FibroGen a leading biopharmaceutical company received orphan drug designation from the U.S. FDA for pamrevlumab for the treatment of Duchenne muscular dystrophy.
Key Market Insights from the report:
The market report has been segmented on the basis, of therapeutic Approach Treatment Type, User, and region.
- By Therapeutic Approach and Treatment Type the duchenne muscular dystrophy treatment market is classified into molecular-based therapies (mutation suppression and exon skipping), steroid therapy (corticosteroids), nonsteroidal anti-inflammatory drugs (NSAIDs), and other therapeutic approaches and treatment end users.
- By End-User Duchenne Muscular Dystrophy Treatment, the market is classified into hospitals/clinics, ambulatory centers, and other end users.
- By region, The Asia Pacific market is expected to show the highest CAGR owing to growing awareness about Duchenne muscular dystrophy and growing public and private healthcare insurance coverage. North America is expected to dominate the market. Owing to product innovations, great healthcare expenditure, and support of government awareness programs.
Request a free sample of our research report @ https://www.prophecymarketinsights.com/market_insight/Insight/request-sample/3969
Browse 60 market data tables* and 35 figures* through 140 slides and in-depth TOC on “Global Duchenne Muscular Dystrophy Treatment Market By Therapeutic Approach and Treatment (Molecular-based Therapies (Mutation Suppression, and Exon Skipping), Steroid Therapy (Corticosteroids), Nonsteroidal Anti-inflammatory Drugs (NSAIDs) and Other Therapeutic Approaches and Treatment End Users), By End User (Hospitals/Clinics, Ambulatory Centers, and Other End Users), and By Region (North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa) - forecast till 2034"
The key players operating the Duchenne Muscular Dystrophy Treatment market include BioMarin, Bristol-Myers Squibb Company, Fibrogen Inc., Eli Lilly and Company, Nobelpharma Co. Ltd, NS Pharma Inc., Pfizer Inc., PTC Therapeutics, Santhera Pharmaceuticals, and Sarepta Therapeutics. The Key players in the market are focusing on mutual understanding.
About Prophecy Market Insights
Prophecy Market Insights is a specialized market research, analytics, marketing, and business strategy, and solutions company that offers strategic and tactical support to clients for making well-informed business decisions and to identify and achieving high-value opportunities in the target business area. Also, we help our client to address business challenges and provide the best possible solutions to overcome them and transform their business.
Contact Us:
Prophecy Market Insights
Email- [email protected]
We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports
Custmoized Your ReportWe help clients to procure the report or sections of the report at their budgeted price. Kindly click on the below to avail
Request for Discount
Quick contact
